Protagonist Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2018; filed August 7, 2018. Protagonist is a clinical-stage biopharmaceutical company developing constrained peptide-based drug candidates. Its lead programs were PTG-100 and PTG-200 for inflammatory bowel disease and PTG-300 for anemia and iron-overload disorders.
Financial Performance and Position
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| License and collaboration revenue | $11.7 million | $0 | $22.5 million | $0 |
| Research and development expense | $17.7 million | $12.0 million | $33.1 million | $23.3 million |
| General and administrative expense | $3.2 million | $3.1 million | $6.8 million | $6.1 million |
| Loss from operations | $(9.2) million | $(15.1) million | $(17.5) million | $(29.4) million |
| Net loss | $(8.7) million | $(15.0) million | $(16.3) million | $(29.1) million |
| Basic and diluted loss per share | $(0.41) | $(0.89) | $(0.77) | $(1.73) |
- Q2 operating margin was approximately negative 79%; net margin was approximately negative 74%. Six-month operating and net margins were approximately negative 78% and negative 73%, respectively, based on reported collaboration revenue.
- Cash, cash equivalents and available-for-sale securities totaled $125.2 million at June 30, 2018, compared with $155.5 million at December 31, 2017. Total assets were $137.5 million and accumulated deficit was $117.9 million.
- Net cash used in operating activities was $30.5 million for the first six months of 2018, versus $22.7 million in the comparable 2017 period. Investing activities used $12.3 million, primarily reflecting purchases of marketable securities; financing activities provided $0.6 million.
- The company had no outstanding debt or credit facility. Current liabilities were $29.0 million, including $13.2 million of deferred revenue related to Janssen.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $11.7 million in the quarter and $22.5 million year to date, primarily from recognizing the Janssen collaboration transaction price over time. No product-sales revenue was generated.
- Research and development expense increased 48% in Q2 and 42% year to date. Q2 increases reflected $6.6 million of PTG-200 development expense and $3.1 million of PTG-300 expense, partly offset by lower PTG-100 and discovery costs.
- PTG-200 and PTG-300 advanced into clinical development, while PTG-100 clinical spending declined following discontinuation of its Phase 2b ulcerative-colitis trial in March 2018.
- Research and development headcount increased from 32 employees at June 30, 2017 to 49 at June 30, 2018; total full-time employees were 62.
- Interest income increased to $0.6 million in Q2 and $1.1 million year to date, reflecting investment of the Janssen upfront payment and 2017 equity-offering proceeds.
Collaboration, Outlook, Risks and Unusual Items
- Under the Janssen agreement for PTG-200, the transaction price was estimated at $56.7 million at June 30, 2018, comprising the $50.0 million upfront payment and estimated cost-sharing consideration. The potential $25.0 million IND filing payment remained fully constrained because filing was not considered probable at that date.
- The agreement provides potential additional payments, including $125.0 million and $200.0 million opt-in payments, up to $590.0 million of additional development, regulatory and sales milestones, and tiered royalties. These amounts are contingent and are not assured.
- Management expected Janssen to file a U.S. IND for PTG-200 in the fourth quarter of 2018, supporting a global Phase 2 Crohn’s disease study. PTG-300 received FDA orphan-drug designation for beta-thalassemia, and the company filed a U.S. IND in the second quarter, with global Phase 2 submissions planned for the fourth quarter.
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations for at least the next 12 months from the filing date, but additional capital will be required to advance clinical programs and potentially initiate pivotal trials.
- On August 6, 2018, after quarter-end, the company agreed to sell 2.75 million shares at $8.00 per share for approximately $22.0 million of gross proceeds and issue warrants for 2.75 million shares. Half of the warrants have a $10.00 exercise price and half have a $15.00 exercise price, creating potential future dilution.
- The PTG-100 Phase 2b trial was discontinued after an interim futility analysis indicated an unusually high placebo response. The filing also discusses an August 2018 re-read indicating that some initial endoscopy readings were erroneous and that, using corrected readings, the trial would have continued; management planned discussions with regulators regarding next steps.
- Key risks include continued operating losses, dependence on additional financing and Janssen’s future decisions, clinical-trial failure or delay, regulatory uncertainty, reliance on contract research and manufacturing organizations, intellectual-property challenges, competition, and potential dilution from future equity financings and warrants.
- A patent-infringement action concerning PTG-200 was dismissed without prejudice in February 2018. No amended complaint or appeal was filed, and the company stated that the matter was concluded, while noting that future litigation could occur if commercial activity becomes imminent.
Investor Verification Priorities
- Verify the timing and terms of the August 2018 equity and warrant financing, including dilution and registration rights.
- Verify Janssen’s PTG-200 development progress, U.S. IND filing, Phase 2 initiation, and any opt-in or milestone payments.
- Assess the corrected PTG-100 clinical data and regulatory feedback following the endoscopy re-read.
- Reconcile collaboration revenue recognition with the remaining $13.2 million of deferred revenue and the company’s cost-based performance estimates.
- Monitor cash burn, future financing needs, and whether the stated liquidity runway remains adequate as clinical programs advance.
- Confirm that no debt, material off-balance-sheet arrangements, or additional material legal contingencies have arisen after the filing date.